Bemotrizinol: First FDA‑Approved Broad‑Spectrum UVA Filter in 30 Years
Bemotrizinol (BEMT), the first new sunscreen ingredient approved by the FDA in nearly three decades, will soon be available in the United States as a broad‑spectrum UVA filter that blocks the most penetrative wavelengths between 370 and 400 nanometers.
Key Takeaways
- BEMT is the first FDA‑approved sunscreen ingredient in almost 30 years.
- It blocks the elusive UVA band from 370 to 400 nm, a gap left by current U.S. sunscreens.
- Swiss chemists developed it in the late 1990s; it entered EU markets in 2000.
- DSM‑Firmenich will sell it exclusively as Parsol Shield for 18 months.
- Early, regular use could cut skin‑cancer risk by about 80 % in adulthood.
| Metric | Value | Why it matters |
|---|---|---|
| First FDA‑approved new sunscreen ingredient | Almost 30 years | Marks a major advance in sun protection. |
| UVA coverage | 370–400 nm | Closes a critical gap in U.S. sunscreens. |
| Investment in testing | $US 18 million | Supports safety and efficacy claims. |
| Photostability | 6–8 hours | Longer protection than many existing filters. |
| Potential skin‑cancer reduction | ~80 % | Significant public‑health impact. |
What Is Bemotrizinol?
Bemotrizinol, abbreviated BEMT, is a large‑molecule UV filter that sits on the skin rather than being absorbed. Its size keeps it from entering the bloodstream, and it converts harmful UV energy into harmless heat.
How It Works
BEMT blocks UVA wavelengths from 370 to 400 nm, the most penetrative part of the UVA spectrum that current U.S. sunscreens miss. By covering a 30‑nanometer band, it can prevent mutations that lead to skin cancer.
Development History
Swiss chemists created BEMT in the late 1990s. It entered the European Union market in 2000 and later appeared in Asia, Australia, and Canada. The U.S. delay was due to regulatory differences: U.S. sunscreens are classified as OTC drugs, whereas other countries treat them as cosmetics.
Market Launch and Availability
DSM‑Firmenich will launch BEMT under the brand Parsol Shield. For the first 18 months, it will be sold exclusively in the United States. The company invested $US 18 million in testing its safety and efficacy.
Why It Matters
Because BEMT closes a critical UVA gap and is more photostable, it could reduce skin‑cancer risk by about 80 % if used from early childhood. Its large molecule also reduces the chance of endocrine disruption and coral bleaching, concerns linked to other filters.
“BEMT is the best broad‑spectrumbroad‑spectrum ultraviolet radiation filter available,” says Stanford Medicine dermatologist Susan Swetter.
Frequently Asked Questions
Who developed bemotrizinol?
Swiss chemists in the late 1990s created the molecule, which entered EU markets in 2000.
When will it be available in the U.S.?
It is expected to hit U.S. shelves in September, with an 18‑month exclusive period under the name Parsol Shield.
What makes BEMT different from other UVA filters?
It blocks the 370‑400 nm range that most U.S. sunscreens miss, is photostable for 6–8 hours, and stays on the skin without being absorbed.
Is it safe for children?
Reporting based on: original source.
Comments
Post a Comment